BIO 2015: Antibiotics market could lag for a decade, says patent study
The antibiotics market could lose out for a decade due to inadequate research and development (R&D) in the area, according to a report published by UK law firm Marks & Clerk today, June 16.
The firm presented its report, “From rare to routine”, at the 2015 BIO International Convention in Philadelphia.
By comparing the patenting trends in three therapeutic areas—rare diseases, antibiotics, and vaccines—the report indicated how government incentives to innovate can have an impact on R&D.
It found that since 2004 research into new antibiotics classes has accounted for less than 5% of antibiotics-related patent filings. However, despite the worldwide decline in patent filings in the area, since 2004, the number of patents granted has been increasing year-on-year.
Patents covering modifications of known antibiotics, such as penicillin, are most often filed, though there is some research into entirely new classes, the report said.
Amgen filed the most patents related to new antibiotics, while the two biggest filers of antibiotics patents in both new and known classes are Chinese companies Tianjin Shengji Group and Shandong Xuanzhu Pharmaceutical Technology.
Gareth Williams, a Cambridge-based partner at Marks & Clerk, who co-authored the report, said that China is seen as emerging as a “major force in the field of antibiotics”.
He told LSIPR that Chinese filers in the antibiotics space typically apply for domestic patents, while non-Chinese companies tend to file more widely.
He also noted a trend wher non-Chinese companies are starting to file less widely as they used to, taking a more “targeted approach”.
However, companies in China are not as prolific filers in the rare disease area as those in the US, EU and Japan, said the report. Williams suggested this could be because China does not have the same incentives to innovate in this area.
Accordingly, the report said, pharmaceutical companies Pfizer, Merck, Novartis and Johnson & Johnson are the biggest filers in the area, along with Novartis, GSK and Roche. US companies and universities are also prevalent in the area, it added.
The report showed that public organisations tended to file the most vaccine-related patent applications—the US Department of Health filed more than double the number than any other filer—though veterinary research bodies were also big filers in the area.
Williams told LSIPR that low levels of antibiotic patenting are a concern, but countries including the UK, with its Commission on Antibiotic Resistance, and the US, with the recently announced National Action Plan for Combating Antibiotic-Resistant Bacteria, are working to address the problem.
He said in the report: “We hope the results of these reviews, together with increasing public pressure and media attention, will result in an increase in research into antibiotics, particularly from big pharma. The USA is a clear leader in this area, but the statistics suggest it is less dominant than in rare diseases and vaccines, with China in particular innovating more and more.”
The 2015 BIO International Convention is taking place in Philadelphia from June 15 to 18.
BIO 2015, antibiotics, report, Marks & Clerk, incentives, Biotechnology Industry Organization, patent
生物2015：抗生素市场可能会滞后十年，说专利研究抗生素市场可能失去了由于研发不足十年（研发）的面积，根据英国法律公司Marks & Clerk今天发表的一份报告，六月十六日。
该公司提交了一份报告，“从罕见的常规”，在2015 BIO国际大会在费城。
通过比较三个治疗领域的罕见疾病，抗生素和疫苗的专利申请趋势，报告指出政府如何鼓励创新，可以对研发的影响
研究发现，自2004以来，研究新的抗生素类占比不到5%，相关的专利申请量的抗生素。然而，尽管在该地区的专利申请量下降，全球2004以来，授予的专利数量一直在增加，同比。
专利涵盖已知抗生素的修改，如青霉素，最常提起的，虽然有一些研究的全新类型，报告说。
安进公司提交的最新抗生素的相关专利，而最大的在新的和已知的类中国企业天津盛基集团和山东轩竹医药科技抗生素专利申报。
加里斯威廉姆斯，一个总部位于剑桥的Marks & Clerk合伙人，谁共同撰写的报告，说中国是新兴的一个“主要的力量在抗生素领域”。
他告诉lsipr在抗生素的中国人典型的空间申请国内专利，而非中国的公司倾向于更广泛的文件。
他还注意到一个趋势，非中国企业开始文件很少像以前那样，以一种更为“目标”的方法。
然而，中国企业没有在罕见病地区多产者是那些在美国，欧盟和日本，报告说。威廉姆斯认为，这可能是因为中国没有这方面的创新同样的动机。
因此，报告说，制药公司辉瑞，默克，诺华公司和约翰逊&约翰逊在面积最大者，随着诺华和罗氏，葛兰素史克。美国的公司和大学都在该地区还流行，它说。
报告显示，公共机构往往最疫苗相关的专利申请美国卫生部门申请人数增加一倍以上，比任何其他滤波器虽然兽医研究机构也在面积大的申报文件。
威廉姆斯告诉lsipr低水平的抗生素的专利是一个问题，但国家如英国，其委员会对抗生素的耐药性，与美国，与最近公布的国家行动计划对抗耐抗生素的细菌，正在努力解决的问题。
他在报告中说：“我们希望这些评审的结果，在提高公众的压力和媒体的关注，将导致在研究抗生素的增加，尤其是大型制药公司。美国在这方面是一个明确的领导者，但统计数据显示它比罕见的疾病和疫苗不占优势，特别是在创新，越来越多的中国。”
2015 BIO国际大会是在费城，从六月十五日到18。
生物2015，抗生素，报告，Marks & Clerk，激励，生物技术产业组织，专利
